3-(3-Hexylsulfanyl-pyrazin-2-yl)-1-aza-bicyclo[2.2.2]octan-3-ol | 138449-63-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 奎宁环
• 英文名称: 3-(3-Hexylsulfanyl-pyrazin-2-yl)-1-aza-bicyclo[2.2.2]octan-3-ol
• 英文别名: 3-(3-Hexylsulfanylpyrazin-2-yl)-1-azabicyclo[2.2.2]octan-3-ol
• CAS: 138449-63-5
• 化学式: C₁₇H₂₇N₃OS
• 分子量: 321.487
• InChiKey: YBNQFRUWBWXPIS-UHFFFAOYSA-N

物化性质

• 沸点：
  476.3±45.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  74.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(3-Hexylsulfanyl-pyrazin-2-yl)-1-aza-bicyclo[2.2.2]octan-3-ol 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 以1.265 g的产率得到3-Chloro-3-(3-hexylsulfanyl-pyrazin-2-yl)-1-aza-bicyclo[2.2.2]octane
  参考文献：
  名称：

  Functionally selective M1 muscarinic agonists. 3. Side chain and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles

  摘要：

  In an attempt to improve upon the M(1) agonist activity of the selective M(1) agonist xanomeline and related compounds, the M(1) muscarinic efficacies and potencies of 3- and 6-substituted pyrazinylazacycles were varied by changing both the 3- and 6-substituents as well as the azacycle. Significant improvements in efficacy and potency over the previously prepared [3-(hexyloxy)pyrazinyl]tetrahydropyridine 19 were obtained with the [3-(hexyloxy)pyrazinyl]quinuclidine 5i. The M(1) activity of 5i showed some enantioselectivity with (S)-5i being ca. 4-fold more potent than (R)-5i. Like 19 and xanomeline, 5i was a functionally selective M(1) agonist that showed greater functional selectivity than widely studied pyrazinylquinuclidine 5n (L-689,660). The improved functional selectivity of 5i over 5n could be attributed to the additional binding interactions between the hexyloxy side chain of 5i and the M(1) receptor that are not available to 5n. Although 5i may show M(1) functional selectivity comparable to xanomeliine, 5i is a less efficacious and potent M(1) agonist than xanomeline.

  DOI：

  10.1021/jm00018a007
• 作为产物：
  描述：

  3-奎宁环酮 在 正丁基锂 、 sodium hydride 、 2,2,4,4-tetramethylpiperidine 作用下， 反应 4.5h， 生成 3-(3-Hexylsulfanyl-pyrazin-2-yl)-1-aza-bicyclo[2.2.2]octan-3-ol
  参考文献：
  名称：

  Functionally selective M1 muscarinic agonists. 3. Side chain and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles

  摘要：

  In an attempt to improve upon the M(1) agonist activity of the selective M(1) agonist xanomeline and related compounds, the M(1) muscarinic efficacies and potencies of 3- and 6-substituted pyrazinylazacycles were varied by changing both the 3- and 6-substituents as well as the azacycle. Significant improvements in efficacy and potency over the previously prepared [3-(hexyloxy)pyrazinyl]tetrahydropyridine 19 were obtained with the [3-(hexyloxy)pyrazinyl]quinuclidine 5i. The M(1) activity of 5i showed some enantioselectivity with (S)-5i being ca. 4-fold more potent than (R)-5i. Like 19 and xanomeline, 5i was a functionally selective M(1) agonist that showed greater functional selectivity than widely studied pyrazinylquinuclidine 5n (L-689,660). The improved functional selectivity of 5i over 5n could be attributed to the additional binding interactions between the hexyloxy side chain of 5i and the M(1) receptor that are not available to 5n. Although 5i may show M(1) functional selectivity comparable to xanomeliine, 5i is a less efficacious and potent M(1) agonist than xanomeline.

  DOI：

  10.1021/jm00018a007

文献信息

• Functionally selective M1 muscarinic agonists. 3. Side chain and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles
  作者：John S. Ward、Leander Merrit、David O. Calligaro、Frank P. Bymaster、Harlan E. Shannon、Barry D. Sawyer、Charles H. Mitch、Jack B. Deeter、Steven C. Peters

  DOI：10.1021/jm00018a007

  日期：1995.9

  In an attempt to improve upon the M(1) agonist activity of the selective M(1) agonist xanomeline and related compounds, the M(1) muscarinic efficacies and potencies of 3- and 6-substituted pyrazinylazacycles were varied by changing both the 3- and 6-substituents as well as the azacycle. Significant improvements in efficacy and potency over the previously prepared [3-(hexyloxy)pyrazinyl]tetrahydropyridine 19 were obtained with the [3-(hexyloxy)pyrazinyl]quinuclidine 5i. The M(1) activity of 5i showed some enantioselectivity with (S)-5i being ca. 4-fold more potent than (R)-5i. Like 19 and xanomeline, 5i was a functionally selective M(1) agonist that showed greater functional selectivity than widely studied pyrazinylquinuclidine 5n (L-689,660). The improved functional selectivity of 5i over 5n could be attributed to the additional binding interactions between the hexyloxy side chain of 5i and the M(1) receptor that are not available to 5n. Although 5i may show M(1) functional selectivity comparable to xanomeliine, 5i is a less efficacious and potent M(1) agonist than xanomeline.